In the past decade, a series of preliminary clinical studies has explored the efficacy and safety of Hb-DBS for treatment-refractory psychiatric disorders (Yadid et al., 2013; Zhang C. et al., 2019, 2022; Wang Y. et al., 2020; Zhang C. et al., 2021). This evidence concerns the gene GSTM1 and psychiatric disorder.